In the past, the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) for different forms of cancer, such as non-small cell lung cancer (NSCLC) and melanoma. More recently,…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Rare Community Profiles Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families,…
The later part of 2023 will see decisions on drugs in four areas such as advanced melanoma, sickle cell disease, Alzheimer’s disease, and depression. BioSpace shines the spotlight on…
Each year, there are less than 600 new cases of papillary craniopharyngioma (PCP) diagnosed within the United States. While PCP typically has a good prognosis with treatment, treatment is…
It’s no secret that our gut health plays a formative role in our overall health. Over the past decade, more and more studies have examined how the gut microbiome impacts…
Before you read on, make sure to check out: Part 1 of our article: Green Bay Packers' Shemar Jean-Charles and Los Angeles Chargers' Storm Norton discuss why they raise Alzheimer's disease…
At 41 years old, Teddi Mellencamp has done many great things in her life. The daughter of singer-songwriter John Mellencamp, Teddi is a successful podcast host and a reality television…
Currently, the standards-of-care for advanced/metastatic (stage III or IV) melanoma include immunotherapy, targeted therapy, and radiation. Some patients are given anti-PD-1 inhibitors. However, only around 20-30% of those living…
Inside Precision Medicine recently featured an article focusing on biomarkers that suggest the likelihood of drugs called checkpoint inhibitors to “backfire” during melanoma treatment. Checkpoint inhibitors are one of the…
According to a story from AJMC, there are a number of factors in play when determining the path forward for the treatment of advanced melanoma. For this story, Dr. Omid…
According to a press release by Merck & Co. issued on June 24, the European Commission has approved the use of adjuvant Pembrolizumab to treat resected stage IIB/C melanoma. "Adjuvant"…
Maria’s message is: “when in doubt, get a biopsy." Ten years ago, Maria Sylvia noticed a vertical streak on her thumbnail that at the time she thought was “cool." She…
According to a story from Biopharma Dive, the US Food and Drug Administration (FDA) has recently approved a treatment for a rare form of melanoma that affects the eyes, called…
Over the last 10+ years, there have been extreme advances in the treatment of metastatic melanoma. In particular, researchers have sought to develop therapies which halted cancer progression and reduced…
On December 2, 2021, Ultimovacs ASA ("Ultimovacs") announced via news release that its universal cancer vaccine, UV1, received Orphan Drug designation from the FDA. UV1 is designed for those…
The primary cause of death in melanoma patients is widespread metastases. Currently, there is no cure in cases of relapse or in advanced stages. A recent article in Science…
St. Jude Children's Research Hospital has recently announced that its team of scientists have established a registry for pediatric melanoma. The goal is to use data from this registry for…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Over the last 50 years, doctors have been working to improve clinical outcomes for patients with a rare but aggressive form of ocular cancer: uveal melanoma. However, there has been…
From April 5 - 30, the American Chemical Society meets to hold ACS Spring 2021, where chemistry professionals meet to discuss new research and knowledge in their field. During the…
First formed and launched within the UPstart incubator at the University of Pennsylvania's Penn Center for Innovation (PCI), biopharmaceutical company Linnaeus Therapeutics, Inc. ("Linnaeus") is now making strides in the…
On March 11, 2021, global biopharmaceutical company Alkermes plc shared that its investigational drug candidate nemvaleukin alfa received Orphan Drug designation from the FDA. The treatment is designed for patients…
Earlier this week, biotechnology company Syntrix Pharmaceuticals ("Syntrix") announced that it had finished dosing all patients in its Phase 1/2 clinical trials. The trials were designed to evaluate SX-682 as a…
According to a recent report in the Journal of Clinical Oncology, over one thousand patients with high-risk stage III melanoma were included in the Keynote-054 clinical trial (NCT02362594). The…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
